
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SUV420H2 CRISPR/Cas9 KO Plasmid (h) | sc-404626 | 20 µg | $397.00 |
KMT5C encodes the lysine methyltransferase SUV420H2, a chromatin-modifying enzyme that catalyzes trimethylation of histone H4 lysine 20 (H4K20me3). This mark is enriched in heterochromatin and supports higher-order chromatin compaction, replication timing control, and maintenance of genome stability through regulation of DNA repair pathway choice. SUV420H2 activity interfaces with epigenetic silencing programs and cell-cycle–linked chromatin remodeling, influencing transcriptional repression at repetitive elements and lineage-specific loci. Dysregulation of H4K20 methylation patterns and altered SUV420H2 expression have been associated with aberrant chromatin states observed in cancer and other genome-instability contexts, making KMT5C a useful node for epigenetics-focused mechanistic studies.
SUV420H2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KMT5C gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KMT5C together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KMT5C open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SUV420H2 protein expression.
This CRISPR knockout system enables efficient generation of KMT5C-deficient cell models for investigation of SUV420H2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.